SCHEMBL11943299

SCHEMBL11943299

CN1CCN(c2c(N3CCN(S(=O)(=O)c4ccc(Br)c(Br)c4)CC3)cnn(-c3ccccc3)c2=O)CC1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 3/20 0.57
▸ LMNA P02545 3/20 0.57
▸ SMN1; SMN2 Q16637 2/20 0.57
▸ KMT2A Q03164 1/20 0.57
▸ ALDH1A1 P00352 3/20 0.55
▸ DCTPP1 Q9H773 1/20 0.48
▸ MAPT P10636 1/20 0.48
▸ CYP3A4 P08684 1/20 0.47
▸ CYP2C19 P33261 1/20 0.47
▸ PPARG P37231 1/20 0.47
▸ NCOA2 Q15596 1/20 0.47
▸ NCOA1 Q15788 1/20 0.47
▸ NPSR1 Q6W5P4 1/20 0.47
▸ NCOA3 Q9Y6Q9 1/20 0.47
▸ PKM P14618 2/20 0.45
▸ NPC1 O15118 4/20 0.44
▸ RAB9A P51151 3/20 0.44
▸ TSHR P16473 1/20 0.41
▸ GAA P10253 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11943288 0.86 LMNA (0.60) POLBLMNASMN1; SMN2KMT2AALDH1A1
SCHEMBL11943314 0.84 ALDH1A1 (0.52) POLBLMNASMN1; SMN2KMT2AALDH1A1
SCHEMBL11943312 0.83 ALDH1A1 (0.51) POLBLMNASMN1; SMN2KMT2AALDH1A1
SCHEMBL13328760 0.82 LMNA (0.53) POLBLMNASMN1; SMN2KMT2AALDH1A1
SCHEMBL13329124 0.82 POLB (0.54) POLBLMNASMN1; SMN2KMT2AALDH1A1
SCHEMBL11943178 0.80 ALDH1A1 (0.55) POLBLMNASMN1; SMN2KMT2AALDH1A1
SCHEMBL11943201 0.79 POLB (0.53) POLBLMNASMN1; SMN2KMT2AALDH1A1
SCHEMBL11943206 0.79 KMT2A (0.53) POLBLMNASMN1; SMN2KMT2AALDH1A1
SCHEMBL11943283 0.78 MAPT (0.60) POLBLMNASMN1; SMN2KMT2AALDH1A1
SCHEMBL13304476 0.76 SMN1; SMN2 (0.65) POLBLMNASMN1; SMN2KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-20100158992-A1 PIPERAZINE-SUBSTITUTED PYRIDAZINONE DERIVATIVES USEFUL AS GLUCAN SYNTHASE INHIBITORS SCHERING CORPORATION (US) 2010-06-24 — — US disclosed
US-20100158992-A1 PIPERAZINE-SUBSTITUTED PYRIDAZINONE DERIVATIVES USEFUL AS GLUCAN SYNTHASE INHIBITORS SCHERING CORPORATION (US) 2010-06-24 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors MAN2A1, GYS2, MANBA POLB 1088/4885LMNA 929/4885SMN1; SMN2 3911/4885
US-20100158992-A1 PIPERAZINE-SUBSTITUTED PYRIDAZINONE DERIVATIVES USEFUL AS GLUCAN SYNTHASE INHIBITORS DPM1, GMPS, MAN2A1 POLB 1016/4885LMNA 1760/4885SMN1; SMN2 3332/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback